189 related articles for article (PubMed ID: 20499421)
1. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea.
Park HK; Koh WJ; Shim TS; Kwon OJ
Yonsei Med J; 2010 Jul; 51(4):552-6. PubMed ID: 20499421
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium kansasii pulmonary diseases in Korea.
Yim JJ; Park YK; Lew WJ; Bai GH; Han SK; Shim YS
J Korean Med Sci; 2005 Dec; 20(6):957-60. PubMed ID: 16361804
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
5. Clinical and radiological features of Mycobacterium kansasii and other NTM infections.
Matveychuk A; Fuks L; Priess R; Hahim I; Shitrit D
Respir Med; 2012 Oct; 106(10):1472-7. PubMed ID: 22850110
[TBL] [Abstract][Full Text] [Related]
6. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pulmonary disease caused by Mycobacterium kansasii.
Huang HL; Lu PL; Lee CH; Chong IW
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S51-S57. PubMed ID: 32505588
[TBL] [Abstract][Full Text] [Related]
9. Factors which influence treatment initiation for pulmonary non-tuberculous mycobacterium infection in HIV negative patients; a multicentre observational study.
Rawson TM; Abbara A; Kranzer K; Ritchie A; Milburn J; Brown T; Adeboyeku D; Buckley J; Davidson RN; Berry M; Kon OM; John L
Respir Med; 2016 Nov; 120():101-108. PubMed ID: 27817806
[TBL] [Abstract][Full Text] [Related]
10. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
Goldenberg T; Gayoso R; Mogami R; Lourenço MC; Ramos JP; Carvalho LD; Dalcolmo MP; Mello FCQ
J Bras Pneumol; 2020; 46(6):e20190345. PubMed ID: 32696934
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Mycobacterium kansasii Isolates from Respiratory Specimens.
Moon SM; Park HY; Jeon K; Kim SY; Chung MJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Koh WJ
PLoS One; 2015; 10(10):e0139621. PubMed ID: 26431540
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
[TBL] [Abstract][Full Text] [Related]
13. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London.
Davies BS; Roberts CH; Kaul S; Klein JL; Milburn HJ
Scand J Infect Dis; 2012 Nov; 44(11):815-9. PubMed ID: 23078529
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study.
Gommans EP; Even P; Linssen CF; van Dessel H; van Haren E; de Vries GJ; Dingemans AM; Kotz D; Rohde GG
Respir Med; 2015 Jan; 109(1):137-45. PubMed ID: 25464905
[TBL] [Abstract][Full Text] [Related]
15. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection.
Cattamanchi A; Nahid P; Marras TK; Gotway MB; Lee TJ; Gonzalez LC; Morris A; Webb WR; Osmond DH; Daley CL
Chest; 2008 Apr; 133(4):875-80. PubMed ID: 18263685
[TBL] [Abstract][Full Text] [Related]
16. Ethambutol-induced bullous skin lesions in
Kollipara VK; Horowitz M; Lantz J; Nagy-Agren S
Int J Mycobacteriol; 2022; 11(1):120-122. PubMed ID: 35295035
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and epidemiological study of disease caused by Mycobacterium kansasii in the metropolitan area of Bilbao, Spain].
Leal Arranz MV; Gaafar A; Unzaga Barañano MJ; Crespo Notario JA; Cisterna Cáncer R; García Cebrián F
Arch Bronconeumol; 2005 Apr; 41(4):189-96. PubMed ID: 15826528
[TBL] [Abstract][Full Text] [Related]
18. Clinical, radiological and molecular features of Mycobacterium kansasii pulmonary disease.
Bakuła Z; Kościuch J; Safianowska A; Proboszcz M; Bielecki J; van Ingen J; Krenke R; Jagielski T
Respir Med; 2018 Jun; 139():91-100. PubMed ID: 29858008
[TBL] [Abstract][Full Text] [Related]
19. [Nontuberculous mycobacterial infections of the lung].
Latshang TD; Lo Cascio CM; Russi EW
Ther Umsch; 2011 Jul; 68(7):402-6. PubMed ID: 21728159
[TBL] [Abstract][Full Text] [Related]
20. Clinical and radiographic manifestations of uncommon pulmonary nontuberculous mycobacterial disease in AIDS patients.
El-Solh AA; Nopper J; Abdul-Khoudoud MR; Sherif SM; Aquilina AT; Grant BJ
Chest; 1998 Jul; 114(1):138-45. PubMed ID: 9674460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
